SOURCE: Agendia BV

February 05, 2007 03:49 ET

Agendia announces a distribution agreement with Medvet Science, Australia.

First MammaPrint® distribution agreement for Oceania

AMSTERDAM, THE NETHERLANDS -- (MARKET WIRE) -- February 5, 2007 --


Agendia B.V. (Amsterdam, The Netherlands) and Medvet Science (Adelaide, Australia), the wholly owned subsidiary of the Institute of Medical and Veterinary Science, one of Australia's leading medical research organisations and a major provider of medical testing services to hospitals and the community in Australia, have entered into an exclusive distribution agreement for distribution of the MammaPrint breast cancer gene prognosis test in Australia.

In 2002 a 70-gene tumor expression profile was established as a powerful predictor of disease outcome in breast cancer patients. To facilitate its use in a diagnostic setting, the 70-gene prognosis profile was translated into a customized microarray named MammaPrint®. MammaPrint® clearly demonstrated that microarray technology can be used as a reliable diagnostic tool in the prognosis of breast cancer. The test is therefore an excellent tool to predict outcome of disease in breast cancer patients., The result may help a doctor in planning appropriate follow-up for a patient when used with other clinical information and laboratory tests.

Dr. Bernhard Sixt, Chief Executive Officer at Agendia comments: "After the successful introduction of MammaPrint® in Europe, Agendia's priority is now to make the test globally available to patients and clinicians. This agreement is the first important step to access the market in Oceania."

Mr Greg Johansen, General Manager Medvet Science comments: "This is the start of an exciting new area in treatment of women with breast cancer in Australia. We as Medvet consider MammaPrint® as a leading test method in improving breast cancer treatment in Australian women who have already undergone the trauma of breast surgery."

"This test has the possibility to substantial reduce consequences and associated costs of post-operative treatment on women who have undergone this major surgery whilst improving clinical management."

"We look forward to the exciting challenge of introducing this new technology to the surgeons and medical practitioners in Australia."

About Agendia

Agendia is world leader in gene expression analysis-based diagnostics. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first to commercialize a prognostic test - MammaPrint® - that predicts the chance of breast cancer recurrence. Agendia maintains close ties with NKI/AVL, ensuring access to the latest developments in cancer research. Apart from the development of new cancer diagnostics, Agendia offers its expertise in finding new predictive gene expression profiles to companies focusing on new drug development in the area of oncology.

More information about Agendia BV is available at www.agendia.com

CONTACT INFORMATION:

Bernhard Sixt, CEO of Agendia, tel: +31-20-5129161, or Bernhard.sixt@agendia.com

About Medvet Science

Medvet Science is the wholly owned subsidiary of the Institute of Medical and Veterinary Science, one of Australia's leading medical research organisations and a major provider of medical testing services to hospitals and the community in Australia.

The main laboratories of the IMVS are based in Adelaide, South Australia and Medvet Science also has its offices and laboratories based in South Australia and Northern Territory.

Medvet Science acts as the commercialization arm for the Institute of Medical and Veterinary Science

More information about Medvet is available at www.medvet.com.au

CONTACT INFORMATION:

Greg Johansen, General Manager, Medvet Science, tel: +61 (0)88132740, or gjohansen@medvet.com.au

Contact Information